Gilead Sciences (GILD) has shared an update.
Gilead Sciences, Inc. successfully completed its acquisition of CymaBay Therapeutics, Inc., marking a significant move in the pharmaceutical industry. The deal, valued at approximately $4.3 billion, involved a tender offer where a majority of CymaBay’s shares were purchased at $32.50 each. This strategic merger is expected to enhance Gilead’s position in the market by expanding its portfolio with CymaBay’s promising therapeutic projects.
Learn more about GILD stock on TipRanks’ Stock Analysis page.
